Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -210.13% is 376% below its 5-year average of -44.10%, near the low end of its 5-year range (-210.13%–-10.33%).
As of the fiscal period ended Tuesday, June 30, 2026. 139.01% below its 12-month average of -87.92%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -210.13%.
RETURN ON EQUITY (ROE)
-210.13%
RETURN ON EQUITY (ROE) AVG TTM
-87.92%
RETURN ON EQUITY (ROE) AVG 3Y
-45.14%
RETURN ON EQUITY (ROE) AVG 5Y
-44.10%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-139.01%
CURRENT VS 3Y AVG
-365.51%
CURRENT VS 5Y AVG
-376.44%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.76%
median of 687 covered companies
CURRENT VS SECTOR MEDIAN
-415.54%
vs the sector median at left
Alpha Tau Medical Ltd
Market Cap
$1.32B
Return on Equity (ROE)
-210.13%
TTM Avg
-87.92%
3Y Avg
-45.14%
5Y Avg
-44.10%
Market Cap
$1.34B
Return on Equity (ROE)
N/A
TTM Avg
36.18%
3Y Avg
36.18%
5Y Avg
36.18%
Market Cap
$1.35B
Return on Equity (ROE)
N/A
TTM Avg
44.32%
3Y Avg
153.88%
5Y Avg
43.56%
Market Cap
$1.27B
Return on Equity (ROE)
N/A
TTM Avg
76.67%
3Y Avg
76.67%
5Y Avg
76.67%
Market Cap
$1.39B
Return on Equity (ROE)
N/A
TTM Avg
-244.46%
3Y Avg
-323.47%
5Y Avg
-258.47%
Market Cap
$1.39B
Return on Equity (ROE)
N/A
TTM Avg
41.79%
3Y Avg
41.79%
5Y Avg
41.79%
Market Cap
$1.24B
Return on Equity (ROE)
-36.81%
TTM Avg
-43.14%
3Y Avg
-42.82%
5Y Avg
-37.59%
Market Cap
$1.42B
Return on Equity (ROE)
9.00%
TTM Avg
8.29%
3Y Avg
7.90%
5Y Avg
8.39%
Market Cap
$1.42B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Tau Medical Ltd (DRTS) | $1.32B | -210.13% | -87.92% | -45.14% | -44.10% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.34B | N/A | 36.18% | 36.18% | 36.18% |
| Omeros Corporation (OMER)vs › | $1.35B | N/A | 44.32% | 153.88% | 43.56% |
| Kardigan, Inc. (KARD)vs › | $1.27B | N/A | 76.67% | 76.67% | 76.67% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | -244.46% | -323.47% | -258.47% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.39B | N/A | 41.79% | 41.79% | 41.79% |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | -36.81% | -43.14% | -42.82% | -37.59% |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 9.00% | 8.29% | 7.90% | 8.39% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 1849.06% | -120.25% | -118.83% | -82.76% |
| Omada Health (OMDA)vs › | $1.22B | 1.70% | -39.25% | -48.34% | -48.34% |
ROE
-210.1%
ROA
-69.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -210.13% |
| 2026-03-31 | -82.01% |
| 2025-12-31 | -55.29% |
| 2025-09-30 | -51.51% |
| 2025-06-30 | -40.64% |
| 2025-03-31 | -57.63% |
| 2024-12-31 | -50.67% |
| 2024-09-30 | -42.71% |
| 2024-06-30 | -37.33% |
| 2024-03-31 | -36.62% |
| 2023-12-31 | -34.52% |
| 2023-09-30 | -28.03% |
| 2023-06-30 | -24.74% |
| 2023-03-31 | -16.34% |
| 2022-12-31 | -31.95% |
| 2022-09-30 | -58.74% |
| 2022-06-30 | -60.20% |
| 2022-03-31 | -74.64% |
| 2021-09-30 | -10.33% |
| 2021-03-31 | -7.34% |
| 2020-09-30 | -16.85% |
| 2020-03-31 | -27.70% |
